Germline mutation status of BRCA1/2 as biomarker: Higher pCR rates observed in mutations carriers in all arms. Mutation carriers and non-carriers benefitted most from weekly nab-paclitaxel.
Analysis from GeparX-trial presented at #SABCS23 #breastcancer